Imdelltra (Tarlatamab)

Tarlatamab is a cancer medicine used to treat a fast-growing kind of lung cancer called small cell lung cancer. It is given as an infusion into a vein. It works by linking the body's immune cells to cancer cells so the immune system can attack them.

Brand names:Imdelltra
Medication

What people taking Imdelltra (Tarlatamab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Imdelltra (Tarlatamab) for Small Cell Lung Cancer?

NameHow it went

About Imdelltra (Tarlatamab)

What It's For

Tarlatamab, sold as Imdelltra, is an immunotherapy for small cell lung cancer, one of the two main types of lung cancer and the one with a tendency to spread early. It is approved for adults with extensive stage small cell lung cancer whose cancer has grown during or after platinum-based chemotherapy, the usual first treatment. Extensive stage means the cancer has spread beyond the lung, the area between the lungs and the lymph nodes above the collarbone to other parts of the body. The US Food and Drug Administration (FDA) first gave tarlatamab accelerated approval in 2024, then full approval in November 2025 after a large trial found that people lived longer on it than on standard chemotherapy given as a second treatment. It is not approved as a first treatment, for limited stage disease or for non-small cell lung cancer.

How It Works

Tarlatamab is a bispecific T-cell engager: a lab-made antibody with two different arms. One arm attaches to DLL3, a protein on the surface of small cell lung cancer cells. The other attaches to CD3, a protein on T cells, a type of immune cell that can kill other cells. By holding the two together, tarlatamab brings T cells into direct contact with the cancer cells, switches them on and directs them to destroy those cells. Activated T cells release cytokines, chemical signals that drive inflammation. That release is part of how the medicine works, but when it is strong it causes cytokine release syndrome, the main early side effect, and the immune activation can also affect the brain and nerves. This is why treatment starts with a small dose and the first infusions are watched closely.

Dosage & Administration

Tarlatamab is given in a clinic or hospital as a one-hour infusion into a vein. Treatment starts with a small step-up dose of 1 mg on day 1, then 10 mg on day 8 and day 15, and then 10 mg every two weeks for as long as it keeps the cancer under control and side effects stay manageable. The dose is not lowered for side effects; instead a dose may be delayed, or treatment stopped. The first two doses need the most planning. Before each one, people receive a steroid to dampen the immune reaction, and afterward intravenous fluids. The care team monitors people for 6 to 8 hours from the start of these infusions and checks them again the next day. For 48 hours after each of these first two doses, people are advised to stay within an hour of an appropriate hospital or treatment center, with a caregiver present. Later visits have shorter observation periods, eventually about 2 hours. Blood counts and liver tests are checked before doses. If a dose is delayed for several weeks, treatment may need to restart with the small step-up dose.

Side Effects

The most common side effects are cytokine release syndrome, tiredness, reduced appetite, changes in taste, fever, constipation, muscle and joint pain, and nausea. Taste changes and poor appetite can make eating harder over months of treatment, so they are worth raising early with the care team. Cytokine release syndrome (CRS) carries an FDA boxed warning, the agency's most prominent kind of warning, because it can be life-threatening or fatal. It affected more than half of people in the trials, though most cases were mild or moderate. It mostly follows the first two doses, often starting around 16 hours after the infusion, which is why the first days are monitored so closely. Fever, feeling dizzy or lightheaded (a sign of low blood pressure), a racing heartbeat, trouble breathing, headache, or nausea and vomiting after leaving the clinic need immediate medical attention. The boxed warning also covers neurologic side effects, including ICANS (immune effector cell-associated neurotoxicity syndrome), a brain effect of the immune activation. ICANS affected about 1 in 10 people and can appear weeks after a dose. Confusion, unusual sleepiness, trouble speaking, shaking, unsteadiness, weakness or numbness in the arms or legs, or a seizure need immediate contact with the care team. Tarlatamab can also cause serious infections, especially pneumonia, as well as low blood counts and liver injury, which the regular blood tests are meant to catch. Later in treatment, a fever or a new cough can signal infection and should be reported right away. Severe allergic reactions, such as a rash or wheezing, are uncommon and need immediate medical attention.

Interactions & Warnings

The prescribing information lists no medicines that must be avoided with tarlatamab and no conditions that rule it out entirely, but the care team should still know about every medicine and supplement being taken. Because neurologic side effects can affect alertness and coordination, people should not drive or operate heavy or dangerous machinery while they have any neurologic symptoms, and until those symptoms have cleared. Tarlatamab may harm a developing baby. Anyone who could become pregnant has a pregnancy test before starting and needs effective contraception during treatment and for 2 months after the last dose. Breastfeeding is not recommended during treatment or for 2 months afterward. The main trials included people who could manage at least light daily activities, and excluded people with brain metastases causing symptoms or an active immune deficiency. How well tarlatamab works, and how safe it is, in people outside those groups is less certain.

What to Expect

The first two weeks are the most demanding: two infusions with long observation, a check the next day, and 48 hours each time staying close to a treatment center with a caregiver. After that, most people settle into an infusion every two weeks with shorter visits and blood tests beforehand. In the main trial, which compared tarlatamab with standard chemotherapy (most often topotecan) in people whose cancer had grown after platinum chemotherapy, half of the people on tarlatamab lived longer than 13.6 months, compared with 8.3 months on chemotherapy. The time before the cancer grew again was only modestly longer (4.2 versus 3.2 months), and people on tarlatamab reported less breathlessness at 18 weeks. In an earlier trial, tumors shrank in about 4 in 10 people, and those responses lasted a median of about 10 months. These are averages, and responses vary widely from person to person. Scans during treatment show whether the cancer is shrinking, stable or growing. Treatment continues while it is working and side effects are manageable. If the cancer grows or side effects become too serious, the care team will talk through the next options.

Questions to Ask Your Doctor

  1. 1.Why is tarlatamab a good next step for me compared with chemotherapy or a clinical trial?
  2. 2.Where will I be monitored after the first two doses, and how should we plan the 48 hours of staying close with a caregiver?
  3. 3.Which symptoms should my caregiver and I call about right away, and what number do we use at night or on weekends?
  4. 4.How will we know whether it is working, and how often will I have scans and blood tests?
  5. 5.When will it be safe for me to drive during treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.